KZR-8445 TFA
KZR-8445 TFA, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 TFA binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 TFA inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 TFA inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 TFA blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 TFA can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection.
For research use only. We do not sell to patients.
- Formula: C51H62BrF9N8O10
- Molecular Weight:1197.98
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IL-2 |
IL-1β |
IL-6 |
IL-23 |
KZR-8445 (0.1-10000 nM; 24 h) TFA directly targets Sec61α to potently inhibit secretion of IL-2-GLuc and TNFα-GLuc in HEK293 Flp-In T-REx cells expressing WT Sec61α, with an IC50 of ~100 nM[1].
KZR-8445 (24 h) TFA inhibits secretion of GLuc reporters fused to HER3, prolactin, PD1, TNFα, and IL-2 signal peptides in HEK293 Flp-In T-REx cells with IC50 values ranging from 32 nM to 1068 nM[1].
KZR-8445 TFA potently inhibits secretion of Sec61-dependent pro-inflammatory cytokines with submicromolar IC50 values in activated human PBMCs, while sparing cell viability at concentrations up to 20 µM[1].
KZR-8445 (0.01-10 µM; 2 h) TFA inhibits SARS-CoV-2 replication and spike protein biogenesis in Vero E6 cells while maintaining cell viability above 50% at concentrations up to 10 µM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 7-8 weeks old, rheumatoid arthritis induced via intravenous anti-type II collagen antibody cocktail on day 0 + intraperitoneal LPS (HY-D1056) on day 3)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.v.; weekly/weekly; 2 weeks
-
Result:Blocked disease progression with a statistically significant effect at 10 and 20 mg/kg thrice weekly.
Significantly blocked disease progression at 20 mg/kg weekly.
Showed no significant toxicity, with body weight changes comparable to or greater than vehicle-treated mice across all treatment groups.
Chemical Information
-
Molecular Weight 1197.98
-
Formula C51H62BrF9N8O10
-
SMILES
BrC(C=C1)=CC=C1CN2C3=CC=CC=C3C(C[C@@H]4N(C([C@@H](NC([C@@H](N(C([C@@H](NC([C@H](OC([C@@H](N(C([C@@H](NC4=O)CC(C)C)=O)C)C)=O)CCC#N)=O)CC(F)(F)F)=O)C)CC(C)C)=O)CC(F)(F)F)=O)C)=C2.OC(C(F)(F)F)=O.[x]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
KZR-8445 TFA Related Classifications
Cat. No.: HY-P10466A
Powered by Bioz
- KZR-8445
- KZR8445
- KZR 8445
- Sec61
- SARS-CoV
- Interleukin Related
- TNF Receptor
- IFNAR
- signal peptides
- Sec61α
- collagen antibody
- T-cell acute lymphoblastic leukemia cells
- membrane protein biogenesis
- pro-inflammatory cytokines
- Vero E6 cells
- HEK293 Flp-In T-REx cells
- secretory protein biogenesis
- SARS-CoV-2
- Inhibitor
- inhibitor
- inhibit